Logotype for Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals (APLLTD) investor relations material

Alembic Pharmaceuticals Q2 25/26 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Alembic Pharmaceuticals Ltd
Q2 25/26 earnings summary4 Nov, 2025

Executive summary

  • Q2 FY26 revenue grew 16% year-on-year to INR 1,910 crores, with net profit up 20% to INR 185 crores, driven by strong performance across India Branded, US Generics, Ex-US Generics, and API segments.

  • EBITDA before R&D rose 32% year-on-year to INR 503 crores, with margin improving to 26% from 23% last year; EBITDA margin for Q2 FY26 was 17%.

  • R&D investment increased 41% year-on-year to 10% of revenue, supporting accelerated product filings and approvals.

  • Acquisition of UTILITY Therapeutics completed, marking entry into U.S. branded drugs with PIVYA for urinary tract infections.

  • The Board approved unaudited financial results for the quarter and half year ended 30 September 2025.

Financial highlights

  • Half-year revenue up 13% year-on-year to INR 3,621 crores; EBITDA before R&D at INR 927 crores (26% margin), up 28%.

  • Net profit margin for Q2 FY26 was 9.67%, with EPS at ₹9.40, up from ₹7.79 in Q2 FY25.

  • Net working capital increased to INR 2,921 crores from INR 2,734 crores in March 2025.

  • Net debt rose to INR 1,280 crores from INR 967 crores in June 2025, reflecting acquisition and working capital funding.

  • Interest cost increased to INR 76 crores from INR 71 crores sequentially.

Outlook and guidance

  • Net debt (excluding PIVYA launch) expected to gradually reduce in FY 2027 as new products and facilities ramp up.

  • R&D spend guidance maintained at INR 600-650 crores for the year, with future spend expected at 8-10% of revenue.

  • EBITDA margin expected to improve to 18-20% over the next couple of years as utilization and product launches increase.

  • Pipeline includes 10+ product launches in US Generics for H2 FY26.

  • PIVYA launch in late Q4 FY 2026; initial profitability impact expected, with medium- to long-term growth potential.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Alembic Pharmaceuticals earnings date

Logotype for Alembic Pharmaceuticals Ltd
Q3 25/262 Feb, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Alembic Pharmaceuticals earnings date

Logotype for Alembic Pharmaceuticals Ltd
Q3 25/262 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Alembic Pharmaceuticals Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of generic and specialty medicines. The company produces active pharmaceutical ingredients (APIs) and formulations across various therapeutic areas, including cardiology, dermatology, neurology, and anti-infectives. The company is headquartered in Vadodara, India, and its shares are listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE).

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage